Myelodysplastic Syndromes: all 2,165 studies

Page 4 of 22. Open to participants first (322), then studies with results posted, then the rest; newest registration first within each.

• Investigation of the Genetics of Hematologic DiseasesRecruitingNCT02720679
• KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT ChildrenEnrolling by invitationNCT02646839Phase 2
• Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsRecruitingNCT02508038Phase 1
• Cancer Experience Registry (CER) for Cancer Patients and CaregiversRecruitingNCT02333604
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
• HSCT for Patients With Fanconi Anemia Using Risk-Adjusted ChemotherapyRecruitingNCT02143830Phase 2
• Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid LeukemiaRecruitingNCT02115295Phase 2
• Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 MutationRecruitingNCT02074839Phase 1
• Natural History Study of GATA2 Deficiency and Related DisordersRecruitingNCT01905826
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative RegimenRecruitingNCT01890486
• Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood TransplantsAvailableNCT01881334
• Pathogenesis of Hematologic MalignanciesEnrolling by invitationNCT01728402
• Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic SyndromeRecruitingNCT01624805Phase 2
• Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)RecruitingNCT01515527Phase 2
• Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic SyndromeRecruitingNCT01311258
• Characterization of the Mechanisms of Resistance to AzacitidineRecruitingNCT01210274
• Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cellsRecruitingNCT01174108Phase 2
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• Biology Studies of Hematologic CancersEnrolling by invitationNCT00923442
• Collection of Tissue Samples for Cancer ResearchRecruitingNCT00900198
• Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in ChildhoodRecruitingNCT00662090
• A Study to Investigate 14C-bemcentinib in Healthy Male SubjectsCompletedNCT06469138Phase 1Results posted
• Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell TransplantationCompletedNCT05968963Not applicableResults posted
• Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic SyndromesTerminatedNCT05918055Phase 1/2Results posted
• A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)TerminatedNCT05835011Phase 2Results posted
• A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid NeoplasmsTerminatedNCT05787496Phase 1Results posted
• Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid NeoplasmsActive, not recruitingNCT05656248Phase 2Results posted
• Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based TherapyCompletedNCT05583552Phase 2Results posted
• A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)TerminatedNCT05568225Phase 2Results posted
• Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic MalignanciesActive, not recruitingNCT05316701Phase 3Results posted
• Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AMLTerminatedNCT05275439Phase 1Results posted
• Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 DepletionActive, not recruitingNCT05236764Not applicableResults posted
• AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic LeukemiaTerminatedNCT05209152Phase 1Results posted
• A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic SyndromesTerminatedNCT05168202Phase 1Results posted
• BMS-986253 in Myelodysplastic SyndromesTerminatedNCT05148234Phase 1/2Results posted
• Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell MembraneActive, not recruitingNCT05146739Phase 1Results posted
• PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC TransplantationCompletedNCT05120570Phase 1/2Results posted
• Off-the-shelf NK Cells + SCT for Myeloid MalignanciesCompletedNCT05115630Phase 2Results posted
• First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)TerminatedNCT05086315Phase 1/2Results posted
• Removing Transfusion Dependence as a Barrier to Hospice EnrollmentCompletedNCT05063591Not applicableResults posted
• A Study of E7820 in People With Bone Marrow (Myeloid) CancersCompletedNCT05024994Phase 2Results posted
• STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDSTerminatedNCT04878432Phase 2Results posted
• Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1TerminatedNCT04874194Phase 1/2Results posted
• Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMMLCompletedNCT04842604Phase 3Results posted
• MBG453 in Lower Risk MDSTerminatedNCT04823624Phase 2Results posted
• A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS ParticipantsTerminatedNCT04812548Phase 2Results posted
• Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related ChangesActive, not recruitingNCT04802161Phase 2Results posted
• Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic SyndromeTerminatedNCT04797780Phase 3Results posted
• MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic MalignanciesTerminatedNCT04762875Phase 2Results posted
• DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
• A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromeCompletedNCT04745676Not applicableResults posted
• ADCT-301 in Patients With R/R AML, MDS, or MDS/MPNTerminatedNCT04639024Phase 2Results posted
• APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)TerminatedNCT04638309Phase 1Results posted
• A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDSTerminatedNCT04623996Phase 1/2Results posted
• CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AMLCompletedNCT04620681Phase 1/2Results posted
• Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)TerminatedNCT04582864Phase 2Results posted
• To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple MyelomaTerminatedNCT04582539Phase 1/2Results posted
• CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual DiseaseTerminatedNCT04526288Phase 2Results posted
• Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeCompletedNCT04487106Phase 2Results posted
• Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell TransplantationCompletedNCT04339101Phase 2Results posted
• Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)TerminatedNCT04313881Phase 3Results posted
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)TerminatedNCT04266301Phase 3Results posted
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic MalignanciesCompletedNCT04191187Phase 2Results posted
• CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CMLCompletedNCT04151706Phase 2Results posted
• Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative DiseaseCompletedNCT04146038Phase 2Results posted
• Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)TerminatedNCT04095858Phase 3Results posted
• Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic CancersTerminatedNCT04083170Phase 2Results posted
• A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)CompletedNCT04079296Phase 1/2Results posted
• Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell TransplantationActive, not recruitingNCT04060277Phase 2Results posted
• Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSCompletedNCT04055844Phase 2Results posted
• TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)CompletedNCT03959241Phase 3Results posted
• CPX-351 Therapy for MDS After Hypomethylating Agent FailureTerminatedNCT03957876Phase 2Results posted
• Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) MutationActive, not recruitingNCT03953898Phase 2Results posted
• A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).TerminatedNCT03946670Phase 2Results posted
• 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/IICompletedNCT03941769Phase 1/2Results posted
• APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell TransplantCompletedNCT03931291Phase 2Results posted
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell TransfusionCompletedNCT03900715Phase 2Results posted
• TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic MalignanciesActive, not recruitingNCT03849651Phase 2Results posted
• A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver ProblemsCompletedNCT03814005Phase 1Results posted
• Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03813147Phase 1Results posted
• Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT03772925Phase 1Results posted
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationCompletedNCT03755414Phase 1Results posted
• APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)CompletedNCT03745716Phase 3Results posted
• Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell TransplantationCompletedNCT03734601Phase 2Results posted
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical StudyTerminatedNCT03733249Phase 1/2Results posted
• AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and MyelofibrosisTerminatedNCT03718143Phase 2Results posted
• Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDSTerminatedNCT03699475Phase 2/3Results posted
• A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveActive, not recruitingNCT03682536Phase 3Results posted
• Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDSCompletedNCT03660228Not applicableResults posted
• Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)TerminatedNCT03614728Phase 1/2Results posted
• Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant RecipientsCompletedNCT03613727Phase 2Results posted
• A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi AnemiaTerminatedNCT03600909Phase 2Results posted
• A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDSTerminatedNCT03593915Phase 1/2Results posted
• CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic TransplantActive, not recruitingNCT03560752Phase 1Results posted
• Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological MalignanciesTerminatedNCT03465540Phase 1Results posted
• Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood TransplantationCompletedNCT03434730Phase 2Results posted
• A Phase Ib Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 MutationsCompletedNCT03433781Phase 1/2Results posted
• Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDSCompletedNCT03417154Phase 2Results posted

← Myelodysplastic Syndromes overview